2,878 reports of this reaction
2.6% of all CABOZANTINIB reports
#8 most reported adverse reaction
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME is the #8 most commonly reported adverse reaction for CABOZANTINIB, manufactured by Exelixis, Inc.. There are 2,878 FDA adverse event reports linking CABOZANTINIB to PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME. This represents approximately 2.6% of all 112,838 adverse event reports for this drug.
Patients taking CABOZANTINIB who experience palmar plantar erythrodysaesthesia syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME is a less commonly reported adverse event for CABOZANTINIB, but still significant enough to appear in the safety profile.
In addition to palmar plantar erythrodysaesthesia syndrome, the following adverse reactions have been reported for CABOZANTINIB:
The following drugs have also been linked to palmar plantar erythrodysaesthesia syndrome in FDA adverse event reports:
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME has been reported as an adverse event in 2,878 FDA reports for CABOZANTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME accounts for approximately 2.6% of all adverse event reports for CABOZANTINIB, making it a notable side effect.
If you experience palmar plantar erythrodysaesthesia syndrome while taking CABOZANTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.